politics
Eli Lilly opposes codifying Trump-era drug pricing deals into law, CEO says
Lilly CEO David Ricks said the company opposes efforts to pass most favored nation style pricing into law after signing voluntary price-alignment deals with the Trump administration, arguing legislative changes could undermine drug research and U.S. industry innovation.
Apr 1st 2026 · United States
Insights
- Eli Lilly told CNBC it will oppose congressional efforts to turn White House drug pricing agreements into law.
- Lilly was among more than a dozen drugmakers that signed voluntary deals last year to align U.S. prices with those in other wealthy countries.
- CEO David Ricks warned that putting the deals through the legislative process could change terms and harm future drug research and innovation.
- Ricks said Lilly has raised its concerns with the White House and congressional leaders and will use all tools to fight what it calls bad policy.
- The White House has pressed Congress to codify elements of the agreements but has not publicly released draft legislative text.